Replies to post #219436 on Biotech Values

[DewDiligence]

(ENTA)—ABBV CFO Bill Chase on today’s Jefferies webcast:

• Mavyret’s launch has been “stunning.”

• (Duopoly) pricing stability in HCV market has been achieved.

• HCV market will still be treating 300K+ patients per year a decade from now.